NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
NHMRC Glaucoma Guidelines - ANZGIG
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>NHMRC</strong> GUIDELINES FOR THE SCREENING, PROGNOSIS, DIAGNOSIS, MANAGEMENT AND PREVENTION OF GLAUCOMA<br />
Chapter 9 – Medication<br />
Table 9.7: Treatment of glaucoma in children<br />
Medication<br />
class<br />
Beta-blockers<br />
Carbonic<br />
anhydrase<br />
inhibitors<br />
Prostaglandin<br />
analogues<br />
Alpha 2<br />
-agonists<br />
Information on use in children<br />
Beta-blockers are often used as first choice treatment for glaucoma in children<br />
(Moore & Nischal 2007). Beta-blockers should be avoided in premature and small infants<br />
as these agents can cause bradycardia, bronchospasm and hypoglcaemia. In general,<br />
beta-blockers should be used at the lowest concentration and dose possible.<br />
Dorzolamide is reported to be a better choice for children than brinzolamide because its<br />
topical use causes less burning, stinging, and itching (Coppens, Stalmans, Zeven et al 2009).<br />
The use of topical and systemic carbonic anhydrase inhibitors has been associated with<br />
causing metabolic acidosis in infants, which can present as failure to thrive. Therefore infants<br />
on these medications should be observed to ensure they are feeding well and gaining weight.<br />
Despite this potential side effect, topical carbonic anhydrase inhibitors are often used as first<br />
or second choice treatment in young children (Moore & Nischal 2007).<br />
Systemic treatment with acetazolamide is usually last choice, and is used in situations when<br />
glaucoma remains unsatisfactorily controlled with other topical medications or in an attempt<br />
to avoid/delay surgical intervention and prevent further glaucomatous optic neuropathy.<br />
This is based on the increased risk of side effects associated with systemic carbonic anhydrase<br />
inhibitor therapy (Coppens et al 2009).<br />
While prostaglandin analogues substantially reduce IOP in adults, there is some evidence<br />
to suggest that they may not be as effective in reducing IOP in many paediatric glaucomas.<br />
Prostaglandin analogues are usually used as second choice therapy in children but<br />
administration as first choice therapy is acceptable as these agents are often effective in<br />
these settings and are well tolerated with the added convenience of once daily administration<br />
(Moore & Nischal 2007).<br />
Alpha 2<br />
-agonists are contraindicated in children less than two years of age and should only<br />
be used with caution in children younger than seven years of age as children are particularly<br />
sensitive to the central nervous system depressant effects of these medications. Several case<br />
reports of somnolence, respiratory depression and hypotony have been reported after use in<br />
children (Coppens et al 2009). Apraclonidine and brimonidine are usually used as second or<br />
third choice agents in the management of glaucoma in children and are useful as short-term<br />
adjunct therapy pre- and post-surgery (Moore & Nischal 2007). The use of apraclonidine is<br />
usually limited to short-term therapy, while brimonidine may be used long-term (AMH 2009).<br />
Evidence Statements<br />
• Evidence supports using beta-blockers in infants and children where necessary.<br />
• Evidence suggests using beta-blockers with caution in premature and small infants, as bradycardia,<br />
bronchospasm and hypoglycemia have been reported.<br />
• Evidence indicates caution when using topical and systemic carbonic anhydrase inhibitors in children,<br />
in situations where glaucoma is resistant to other treatment and/or prior to surgery.<br />
Women wishing to conceive<br />
Women with childbearing potential, who have glaucoma, should be encouraged to discuss their<br />
reproductive plans with a health care provider prior to becoming pregnant. This allows treatment<br />
choices to be planned appropriately, optimising benefits for the mother and minimising risks for<br />
the foetus by managing and potentially reducing medication exposure during critical early stages<br />
of foetal development. An appropriate treatment plan will depend on the degree of the patient’s<br />
glaucomatous damage, the level of her IOP and personal preferences. It may be appropriate to<br />
offer primary surgical intervention to women with glaucoma who wish to conceive.<br />
National Health and Medical Research Council 131